rivaroxaban / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 97 Diseases   239 Trials   239 Trials   14341 News 


12345678910111213...166167»
  • ||||||||||  apixaban / Generic mfg.
    Journal:  Apixaban versus vitamin K antagonists in patients with antiphospholipid syndrome: a cohort study. (Pubmed Central) -  Jun 26, 2024   
    Patients on apixaban had similar risk of major bleeding compared to warfarin (HR=0.54, 95% CI: 0.201-1.448). In real-life APS patients apixaban appears to be similar to VKA for the prevention of thromboembolism and risk of bleeding, which might suggest that some APS patients could be treated with apixaban.
  • ||||||||||  rivaroxaban / Generic mfg.
    Clinical, Retrospective data:  Antithrombotic prophylaxis with rivaroxaban in patients with prehospital COVID-19: A meta-analysis of two placebo-controlled trials. (Pubmed Central) -  Jun 25, 2024   
    In real-life APS patients apixaban appears to be similar to VKA for the prevention of thromboembolism and risk of bleeding, which might suggest that some APS patients could be treated with apixaban. ?Although this meta-analysis does not support antithrombotic prophylaxis with rivaroxaban in a broad prehospital population with acute COVID-19, the prevention of arterial and venous thrombotic events among rivaroxaban-allocated patients is consistent with the known thromboprophylactic effect of the drug in medically ill patients.
  • ||||||||||  morphine sulphate / Generic mfg.
    Symptomatic Catheter Tip Granuloma in a Patient With High Dose Intrathecal Morphine Therapy: To Explant or Not to Explant (126A) -  Jun 25, 2024 - Abstract #ASA2024ASA_3143;    
    Only three drugs (morphine, baclofen, and ziconotide) are approved by the US Food and Drug Administration (FDA) for use in intrathecal pain pump, but several drugs are used off-label, such as hydromorphone, fentanyl, sufentanyl, ketamine, clonidine, and bupivacaine...This case discusses the use of the combination of long- and short-acting oral opioids in the process of rapid weaning off intrathecal opioids in a patient with an IDDS.CASE HISTORYThe patient is a 66-year-old female with a past medical history significant for pulmonary embolism, deep venous thrombosis (on Xarelto), bipolar disorder, asthma, chronic obstructive pulmonary disease, and chronic low back pain...Her pain is well controlled with oxycontin 30 mg bid and oxycodone 15 mg tid...Will you agree?9)Why did this patient develop granuloma at the tip of intrathecal catheter in the first place? Does it relate to the content of drug or it can happen to anyone with intrathecal drug delivery?10)Your new pain fellow asked if there is anything you can do prevent formation of granuloma in other patients.1
  • ||||||||||  morphine sulphate / Generic mfg.
    Symptomatic Catheter Tip Granuloma in a Patient With High Dose Intrathecal Morphine Therapy: To Explant or Not to Explant (126A) -  Jun 25, 2024 - Abstract #ASA2024ASA_3028;    
    Only three drugs (morphine, baclofen, and ziconotide) are approved by the US Food and Drug Administration (FDA) for use in intrathecal pain pump, but several drugs are used off-label, such as hydromorphone, fentanyl, sufentanyl, ketamine, clonidine, and bupivacaine...This case discusses the use of the combination of long- and short-acting oral opioids in the process of rapid weaning off intrathecal opioids in a patient with an IDDS.CASE HISTORYThe patient is a 66-year-old female with a past medical history significant for pulmonary embolism, deep venous thrombosis (on Xarelto), bipolar disorder, asthma, chronic obstructive pulmonary disease, and chronic low back pain...Her pain is well controlled with oxycontin 30 mg bid and oxycodone 15 mg tid...Will you agree?9)Why did this patient develop granuloma at the tip of intrathecal catheter in the first place? Does it relate to the content of drug or it can happen to anyone with intrathecal drug delivery?10)Your new pain fellow asked if there is anything you can do prevent formation of granuloma in other patients.1
  • ||||||||||  Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Review, Journal:  Overdosing of direct oral anticoagulants (Pubmed Central) -  Jun 25, 2024   
    Does it relate to the content of drug or it can happen to anyone with intrathecal drug delivery?10)Your new pain fellow asked if there is anything you can do prevent formation of granuloma in other patients.1 The sensitization of clinicians is important to ensure a
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Rivaroxaban in a Child with Inherited Thrombophilia and Stroke (Pubmed Central) -  Jun 22, 2024   
    To investigate the efficacy and safety of Rivaroxaban in an aged venous thromboembolism patient population under real-world conditions. No abstract available
  • ||||||||||  Reimbursement, US reimbursement, Journal, Medicare:  Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives. (Pubmed Central) -  Jun 21, 2024   
    The other 4 products (ustekinumab, ibrutinib, sitagliptin, and dapagliflozin) had therapeutic alternatives with higher net prices than the drugs selected for negotiation...Our analyses identify different negotiation scenarios for the first 10 drugs selected for Medicare price negotiation, based on key elements involved in the derivation of the initial price offer. Our analyses can help improve transparency in the negotiation process, because the CMS is not required to reveal the information used in the derivation of price offers.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Journal:  Bailout Distal Internal Carotid Artery Stenting After Carotid Endarterectomy: Indications, Technique, and Outcomes. (Pubmed Central) -  Jun 20, 2024   
    Our analyses can help improve transparency in the negotiation process, because the CMS is not required to reveal the information used in the derivation of price offers. Distal ICA stenting is a useful adjunct in the setting of CEA complicated by inadequate end point or vessel dissection in a surgically inaccessible region of the ICA and can minimize the need for high-risk extensive distal dissection of the ICA in this situation.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
    Review, Journal:  Direct oral anticoagulant therapy in adolescent venous thromboembolism: A systematic review. (Pubmed Central) -  Jun 20, 2024   
    DOAC therapy in adolescent VTE had CR/PR in two-thirds of the patients, with low incidence of VTE recurrence and major bleeding. As there are only two randomized controlled trial (RCTs), future adolescents' studies are required to validate our results.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Journal, Machine learning:  Pleiotropic Effects of Direct Oral Anticoagulants in Chronic Heart Failure and Atrial Fibrillation: Machine Learning Analysis. (Pubmed Central) -  Jun 19, 2024   
    Nevertheless, there are issues related to OAT switching that still need to be fully understood, especially for patients in whom AF and heart failure (HF) coexist. Herein, the effective impact of the therapeutic switching from warfarin to DOACs in HF patients with AF, in terms of cardiac remodeling, clinical status, endothelial function and inflammatory biomarkers, was assessed by a machine learning (ML) analysis of a clinical database, which ultimately shed light on the real positive and pleiotropic effects mediated by DOACs in addition to their anticoagulant activity.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Journal, Adverse events:  Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database. (Pubmed Central) -  Jun 18, 2024   
    Hemorrhage is a common risk with factor Xa inhibitors, with rivaroxaban being the most significant. Apixaban and edoxaban also showed significant association with non-hemorrhagic adverse events, and increased attention to non-hemorrhagic adverse events is needed in clinical use.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Clinical data, Journal:  A Pilot Study Describing DOAC Level Results and Association With Clinical Outcomes. (Pubmed Central) -  Jun 17, 2024   
    More patients were on apixaban than other DOACs, and the most common indication for anticoagulation was deep vein thrombosis (DVT) or pulmonary embolism (PE)...More patients on rivaroxaban had a level out-of-range (n = 10) than in-range (n = 4)...DOAC level results also prompted changes in therapeutic plans for 9 of the patients. DOAC level results did not always correlate with expected outcomes, and further research is warranted to clarify which clinical situations may benefit from ordering DOAC levels.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
    Journal:  A small-molecule hemostatic agent for the reversal of direct oral anticoagulant-induced bleeding. (Pubmed Central) -  Jun 17, 2024   
    HeMo is a small-molecule procoagulant that can counterbalance hemostatic disruption by a thrombin inhibitor (dabigatran) or factor Xa inhibitors (apixaban and rivaroxaban). The compound's effective clot formation and versatility make it a possible option for managing the inherent hemorrhagic risk during DOAC therapy.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Metaplastic breast cancer masquerading as a recurrent haematoma: A case report. (Pubmed Central) -  Jun 14, 2024   
    This was managed as a haematoma and rivaroxaban was withheld...Vacuum-assisted biopsy was performed, and histology returned as metaplastic carcinoma. A recurring 'haematoma' should always prompt a search for a secondary cause, with features such as irregular thickened walls and papillary/nodular components requiring further evaluation with biopsy for histopathological correlation.
  • ||||||||||  warfarin / Generic mfg.
    Journal:  Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a Nationwide Cohort Study. (Pubmed Central) -  Jun 14, 2024   
    A recurring 'haematoma' should always prompt a search for a secondary cause, with features such as irregular thickened walls and papillary/nodular components requiring further evaluation with biopsy for histopathological correlation. Hazard ratios (HR) were calculated using Cox regression analysis with the inverse probability of treatment weighted method to assess the risks of ischaemic stroke (IS), intracranial haemorrhage (ICH) and mortality for users of apixaban (n
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  The Impact of Health Education Based on the Pender Health Promotion Model on Patients with Deep Vein Thrombosis of the Lower Limbs Treated with Rivaroxaban. (Pubmed Central) -  Jun 13, 2024   
    After the intervention, the levels of activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) were higher in the Pender group than in the conventional group (P < .05). The health education based on the Pender health promotion model is effective in patients with lower limb DVT treated with rivaroxaban, which can effectively reduce recurrence and complications, optimize coagulation indexes, and improve the quality of life and nursing care satisfaction by improving the patients' health cognition and health behaviors, which is of great value in clinical application and promotion.
  • ||||||||||  rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
    Clinical, Retrospective data, Review, Journal:  Efficacy and Safety of Rivaroxaban Versus Enoxaparin in Prevention of Recurrence of Venous Thrombo-Embolism Events in Cancer Patients: A Meta-Analysis. (Pubmed Central) -  Jun 13, 2024   
    The health education based on the Pender health promotion model is effective in patients with lower limb DVT treated with rivaroxaban, which can effectively reduce recurrence and complications, optimize coagulation indexes, and improve the quality of life and nursing care satisfaction by improving the patients' health cognition and health behaviors, which is of great value in clinical application and promotion. Rivaroxaban can serve as a viable alternative to enoxaparin, with no appreciable drawbacks, for preventing and managing VTE in patients with malignancy.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Journal:  Applicability and impact of the COMPASS trial in a Canadian population of patients with atherosclerotic disease. (Pubmed Central) -  Jun 9, 2024   
    In a real-world population of 4.4 million adults, there are roughly 20,000 new cases of ASVCD diagnosed yearly, with ?40% being eligible for the addition of low-dose rivaroxaban therapy to antiplatelet therapy. The theoretical implementation of dual antithrombotic treatment in this population could result in a substantial reduction in cardiovascular morbidity and mortality.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Journal:  Selection criteria for anticoagulants: survey of Japanese cardiologists based on their daily clinical practice - the Selection DOAC study. (Pubmed Central) -  Jun 8, 2024   
    Logistic regression analysis revealed that increased concern for adherence enhanced the frequency of selecting edoxaban (odds ratio [OR]?=?2.42; p?=?0.047), with the opposite trend observed for dabigatran (OR = 0.404; p?=?0.029)...This study revealed that edoxaban is the most frequently selected anticoagulant. Although prescribing cardiologists select drugs based on background factors, adherence to medication and information from medical representatives were also crucial factors in the selection process.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Review, Journal:  Anticoagulation in the Management of Acute Pulmonary Embolism-A Review. (Pubmed Central) -  Jun 7, 2024   
    Direct oral anticoagulants, such as apixaban, rivaroxaban, or edoxaban, are currently the preferred agents for the treatment of patients who present with acute PE or for long-term treatment...Novel anticoagulant agents targeting factor XI/XIa are currently being investigated in phases 2 and 3 clinical trials, representing an attractive option in anticoagulation therapies in patients with VTE. For hemodynamically unstable patients, systemic thrombolysis is the treatment of choice, and it may also be of benefit-in reduced dose-for patients with intermediate to high risk who are at risk of hemodynamic collapse.
  • ||||||||||  warfarin / Generic mfg.
    Journal:  Factor Xa Inhibitors versus warfarin in patients with morbid obesity and atrial fibrillation. (Pubmed Central) -  Jun 6, 2024   
    This analysis of real-world data suggests no difference in bleeding or thrombotic outcomes for severely obese patients with NVAF taking Factor Xa Inhibitors compared to warfarin. Overall, our study adds further data to support the use of Factor Xa Inhibitors as an alternative to warfarin in severely obese patients with NVAF.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Journal:  Air pollution and serious bleeding events in high-risk older adults. (Pubmed Central) -  Jun 1, 2024   
    Thus, clinicians may recommend that high-risk individuals limit their outdoor air pollution exposure during periods of increased PM2.5 concentrations. Our findings may inform environmental policies to protect the health of vulnerable populations.